Genmab: Janssen dispute cost DKK 146m in H1

Genmab's ongoing arbitration case with partner Janssen Pharmaceuticals has resulted in the latter withholding DKK 146m in royalty payments during the first half of 2021, the Danish biotech group informs.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR

Even though Genmab's superseller, Darzalex, brought in USD 2.8bn in the first half of 2021 against USD 1.8bn from the same period last year – thereby playing a role in driving the recent guidance upgrade – the Danish biotech group is still able to note some less fortunate news for the period.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading